

Date: Thursday 3rd May 2018

Moderator: Dr Sugamya Mallawathantri
MBBS, FRCP (Lond)
Respiratory Physician
Dubbo Specialist Centre

Venue: Two Doors Wine and Tapas Lounge
The Function Room
215B Macquarie Street
Dubbo

Time: 6.45 pm Registration
7.00 pm Asthma Presentation (dinner included)
COPD Update (20 - 30 min)
9.00 pm Close

Contact: Leila Nehme
Mobile: 0419 873 293
Email: leila.nehme@boehringer-ingelheim.com

Sandra Gayed
Mobile: 0408 466 564
Email: sandra.gayed@boehringer-ingelheim.com

RSVP

To RSVP, please email or text your BI representative (see contact details above)
or fill in your details below and fax back to (02) 8875 8701.

TITLE

PRACTICE PH NUMBER

FIRST NAME

PRACTICE FAX NUMBER

SURNAME

MOBILE

MAILING ADDRESS

Provide your email address to receive further information
about this event and other BI events and products.

EMAIL

POSTCODE

SPECIAL DIETARY REQUIREMENTS

Meeting objectives

Learn about the prevalence of poor asthma control in Australia and the impact of poor asthma control

Review latest guidelines for applying a stepwise approach to asthma management

Learn about the latest pharmacological strategies for asthma patients who require a step up from LABA/ICS therapy

Understand the importance of differentiating between COPD and asthma and their distinct treatment pathways

Clearly understand the benefit, risk and role of different classes of COPD therapy based on current evidence and guidelines

PRIVACY STATEMENT

Boehringer Ingelheim Pty Limited ("BIPL") is bound by the Australian Privacy Principles ("APPs") and adheres to these Principles. The personal information BIPL collects from you on this form and at the event you are registered to attend will be used for the purpose of organising and holding the event you have registered for, enabling you to participate in the event and to provide you with educational and promotional communications about the event and other BIPL events and products ("this purpose"). By registering, you consent to receiving communications from BIPL for this purpose. If you do not provide all or some of the requested personal information to us, we may not be able to register you to attend the event and we will not be able to keep you up-to-date with other BIPL events and products. We may disclose your personal information to third party contractors who we engage to assist us with this purpose. We keep your personal information in secure databases that may be hosted on servers that are located outside of Australia (such as in the USA, Japan, Singapore and Germany), in which case we may disclose your personal information to those overseas hosting providers for that purpose only. We may also disclose your personal information to any entity within the worldwide group of Boehringer Ingelheim companies some of which are located outside of Australia including but not limited to New Zealand, Germany and the USA. Our Privacy Policy (at <https://www.boehringer-ingelheim.com.au/data-privacy>) contains information about how you can access and request the correction of your personal information, how you can make a complaint about a breach of the APPs and how we will deal with your complaint. You can contact BIPL or our Privacy Officer by email at privacyofficer.syd@boehringer-ingelheim.com or on + 61(2) 8875 8800. ®Registered trademark. Educational content developed by Boehringer Ingelheim Pty Limited. ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113. **Reference:** 1. Reddel HK, et al. *Med J Aust* 2015; 202(9): 492-7. AUS/SPI-171087b. Date of preparation: Nov 2017. BISR13108W.

Your invitation to

ACTT

Asthma Control Today & Tomorrow

Almost half of all asthma patients in Australia remain poorly controlled, despite the availability of effective treatments.¹

This meeting - **ACTT: Asthma Control Today and Tomorrow** - will explore the latest strategies for improving patient outcomes in asthma.

Guidance will be provided on the practical assessment of asthma control, and new pharmacological options for stepping up asthma treatment in primary care.

You will also learn about key differentiating features of asthma and COPD. The evidence-based treatment pathway for COPD will be discussed, and contrasted with that for asthma management.